Avalo Therapeutics EBIT

Avalo Therapeutics (AVTX) currently reports a EBIT of $-100M as of September 2026. That compares with $-65M in the prior-year period — down 53.5% year over year. That is below the Healthcare sector average of $2T. Use the charts on this page to explore Avalo Therapeutics's EBIT history and peer comparisons.

Avalo Therapeutics's EBIT decreased from $-65M to $-100M — a 53.5% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Avalo Therapeutics's EBIT of $-100M is lower than the Healthcare sector average of $2T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Avalo Therapeutics reported $-100M in EBIT as of September 2026. That compares with $-65M in the prior-year period — down 53.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-100M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $2T. From there, open related valuation or income-statement pages for Avalo Therapeutics, and consider following AVTX for alerts when major investors trade the stock.